Posaconazole clinical trials

Explore recruiting posaconazole clinical trials.

Recruiting posaconazole studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Posaconazole trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study of posaconazole prophylaxis in patients receiving hematopoietic stem cell allograft (allo-HSC) at high risk of invasive fungal infection (IFI): POSALLO study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection

Poland, Belgium, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression

Germany, Italy, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

France, Germany, Spain, Netherlands, Belgium, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies

Spain, France, Germany, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Posaconazole trials by city

Posaconazole in Toronto Posaconazole in Vancouver Posaconazole in Montreal Posaconazole in Calgary Posaconazole in Edmonton Posaconazole in Ottawa Posaconazole in Winnipeg Posaconazole in Quebec City Posaconazole in Hamilton Posaconazole in Kitchener Posaconazole in London Posaconazole in Halifax Posaconazole in New York Posaconazole in Los Angeles Posaconazole in Chicago Posaconazole in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease